ViiV Healthcare Reports Results of Dual-Drug Regimen in P-III TANGO Study for HIV-1 Infection

 ViiV Healthcare Reports Results of Dual-Drug Regimen in P-III TANGO Study for HIV-1 Infection

ViiV Healthcare Reports Results of Dual-Drug Regimen in P-III TANGO Study for HIV-1 Infection

Shots:

  • The P-III TANGO study involves assessing of Tivicay (dolutegravir) + Epivir (lamivudine) vs tenofovir alafenamide fumarate (TAF) -containing regimen in patients with HIV-1 with maintained viral suppression for at least 6mos. on TAF containing regimen
  • The P-III TANGO study resulted in meeting its 1 EPs i.e, patients with plasma HIV-1 RNA ≥50 c/mL using the FDA snapshot algorithm @48wks., no case of virologic withdrawal or resistance is observed
  • Tivicay (50mg) + Epivir (300mg) is a combination of INI and NRTI and has received approval in the US & EU for the treatment of HIV-1 infection with no ARV treatment history and no resistance to dolutegravir/lamivudine & INI class/lamivudine respectively

Click here to read full press release/ article | Ref: GSK | Image: Apex

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post